Targeting p53-dependent stem cell loss for intestinal chemoprotection

Area of Science:

• Gastroenterology
• Oncology
• Molecular Biology

Background:

• The gastrointestinal (GI) epithelium, rapidly renewing tissue, is maintained by stem cells.
• Chemotherapy and radiotherapy cause dose-limiting GI side effects, impacting cancer patient quality of life.
• p53 is a critical DNA damage response regulator with cell-type-specific outcomes.

Purpose of the Study:

• To investigate the role of p53-dependent PUMA induction in chemotherapy-induced intestinal injury.
• To evaluate PUMA inhibition as a strategy for normal intestinal chemoprotection.

Main Methods:

• Utilized mouse models with genetic ablation of Puma and p53.
• Employed a small-molecule PUMA inhibitor (PUMAi) in vivo and in vitro.
• Assessed LGR5+ stem cell loss, WNT/NOTCH signaling, and apoptosis in colonic organoids.

Main Results:

• p53-dependent PUMA induction mediates chemotherapy-induced lethal GI injury in mice.
• Genetic ablation of Puma, but not p53, protected against lethal GI injury.
• PUMAi prevented stem cell loss, signaling pathway activation, and exhaustion during repeated chemotherapy.
• PUMAi protected human and mouse colonic organoids from chemotherapy-induced damage without affecting cancer cells.

Conclusions:

• Targeting PUMA is a promising strategy for normal intestinal chemoprotection.
• Selective PUMA inhibition preserves p53-dependent stem cell function during chemotherapy.
• This approach spares p53-dependent anti-cancer effects while protecting normal tissues.